5,500 Shares in Cencora, Inc. (NYSE:COR) Purchased by Optas LLC

Optas LLC purchased a new stake in Cencora, Inc. (NYSE:COR) during the first quarter, Holdings Channel reports. The fund purchased 5,500 shares of the company’s stock, valued at approximately $1,336,000.

Several other institutional investors have also recently added to or reduced their stakes in COR. Vanguard Group Inc. acquired a new stake in shares of Cencora during the fourth quarter worth about $4,212,508,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Cencora during the first quarter worth about $66,911,000. PNC Financial Services Group Inc. acquired a new stake in shares of Cencora during the fourth quarter worth about $51,339,000. Los Angeles Capital Management LLC acquired a new stake in shares of Cencora during the first quarter worth about $45,692,000. Finally, Pensioenfonds Rail & OV acquired a new stake in shares of Cencora during the first quarter worth about $37,371,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In related news, Director Dermot Mark Durcan purchased 500 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The stock was purchased at an average cost of $218.58 per share, with a total value of $109,290.00. Following the completion of the acquisition, the director now directly owns 21,876 shares in the company, valued at $4,781,656.08. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Dermot Mark Durcan purchased 500 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The stock was purchased at an average cost of $218.58 per share, with a total value of $109,290.00. Following the completion of the acquisition, the director now directly owns 21,876 shares in the company, valued at $4,781,656.08. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Gina Clark sold 1,874 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $223.86, for a total value of $419,513.64. Following the sale, the executive vice president now directly owns 13,284 shares of the company’s stock, valued at $2,973,756.24. The disclosure for this sale can be found here. Insiders sold a total of 1,956,675 shares of company stock valued at $422,352,056 over the last three months. 15.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

Shares of COR stock traded down $2.66 during trading hours on Friday, hitting $225.30. The stock had a trading volume of 2,859,201 shares, compared to its average volume of 1,758,029. The firm has a market capitalization of $44.94 billion, a PE ratio of 24.65, a PEG ratio of 1.57 and a beta of 0.48. Cencora, Inc. has a twelve month low of $171.65 and a twelve month high of $246.75. The stock’s 50 day moving average is $229.12 and its 200 day moving average is $228.16. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.89 and a quick ratio of 0.53.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, topping the consensus estimate of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The firm had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. During the same period last year, the company earned $3.50 earnings per share. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, research analysts forecast that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were issued a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 0.91%. The ex-dividend date was Thursday, May 9th. Cencora’s dividend payout ratio is presently 22.32%.

Analysts Set New Price Targets

A number of research firms recently weighed in on COR. Robert W. Baird upped their target price on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. SVB Leerink restated an “outperform” rating and set a $275.00 target price on shares of Cencora in a research note on Thursday. Finally, Citigroup upped their target price on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $235.30.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.